Pharma shares buck stock market trend, lead gainers
Drug makers rise, bucking the stock market trend as investors seek defensives. Ranbaxy Laboratories is up 4 percent, while Sun Pharmaceutical Industries gains 4.2 percent after marking an all-time high of 839 rupees.
Wed Aug 13, 2014
Sun bid to address monopoly concern
Mumbai, Aug. 13: Sun Pharma today said it was in discussion with the Competition Commission of India to allay apprehensions about the impact of its acquisition of Ranbaxy Laboratories on the domestic pharmaceutical sector.
Fri Aug 08, 2014
The Indian Express
Sun Pharma-Ranbaxy Lab deal comes under CCI scanner
Competition Commission of India would take a final view on the deal after receiving details from them and could seek more information if it is not satisfied with the responses.
Mon Aug 04, 2014
Ranbaxy Laboratories 1QFY2015 performance highlights and results update
For 1QFY2015, Ranbaxy Laboratories posted a lower-than-expected set of results. For the period, sales came in at Rs.2,372cr V/s Rs.2,633cr in 2QFY2014, ie a yoy de-growth of 9.9%.
Wed Jul 30, 2014
Sun Pharma to seek shareholders nod for Ranbaxy acquisition
Mumbai-based Sun Pharmaceutical Industries will seek shareholders nod for its $4 billion acquisition of Ranbaxy Laboratories in a court convened meeting on August 22. In a filing to the BSE, the company said the meeting would be held at Vadodara on August 22, 2014.
Tue Jul 29, 2014
Ranbaxy Laboratories quarterly net loss narrows to Rs 185.92 cr
Drug firm Ranbaxy Laboratories today reported consolidated net loss of Rs 185.92 crore for the quarter ended June 30, 2014.
Mon Jul 28, 2014
Interview with Dinesh Thakur, ISPE Annual Meeting Keynote Speaker
Unprecedented regulatory actions such as the invocation of the Application Integrity Policy, a highly restrictive and cumbersome Consent Decree, and successive import alerts have emphasized the risks to the pharmaceutical supply chain, especially when sourcing API, intermediates, excipients from countries like India and China.
Thu Jul 24, 2014
Cipher Pharmaceuticals and Ranbaxy Announce Distribution Agreement for Isotretinoin Product in Brazil
Cipher will supply the product to Ranbaxy and product manufacturing will be done by Cipher's partner, Galephar Pharmaceutical Research.